Printer Friendly

INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES EQUITY OFFERING

     INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES EQUITY OFFERING
    TORONTO, Nov. 15 /PRNewswire/ -- International Murex Technologies Corporation (AMEX: MXX; TSE) today announced that it has engaged in an equity offering, through a syndicate led by Deacon Barclays de Zoete Wedd Limited.
    The offering will be conducted in Europe and elsewhere outside of North America.  As was the case in the company's successful May 1991 financing, this offering will be placed with various institutions at prevailing market prices.  The financing is set to close in December 1991, subject to receipt of company and regulatory approvals.
    The net proceeds of the offering will be used by MXX to continue its ongoing acquisition program, including the proposed acquisition from the Wellcome Foundation Limited (Wellcome) of its diagnostics division, Wellcome Diagnostics, and for general working capital requirements.  On Nov. 5, the company announced that it had entered into negotiations with Wellcome with respect to the proposed acquisition. The completion of these negotiations is subject to the company's satisfactory review of the business to be acquired, as well as negotiation and execution of definitive documentation.
    Toronto-based MXX is an international medical diagnostic systems company dedicated to the development, manufacture and global marketing of cost-effective diagnostic tests for infectious diseases and products for the blood banking industry.
    -0-                 11/15/91
    /CONTACT:  C. Robert Cusick, president and chief executive officer, or Marcia M. Young, of International Murex Technologies, 800-688-1332 or 416-408-4682/
    (MXX) CO:  International Murex Technologies Corporation; Wellcome Foundation
     Limited ST:  Ontario, Georgia IN:  MTC SU:  OFR BR-BN -- AT007 -- 1513 11/15/91 11:48 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1991
Words:257
Previous Article:KENTUCKY CENTRAL LIFE INSURANCE COMPANY REPORTS RESULTS
Next Article:D.O.C. OPTICS CORPORATION REPORTS THIRD-QUARTER RESULTS
Topics:


Related Articles
INTERNATIONAL MUREX REPORTS NOTIFICATION OF 13-D FILING
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES THIRD QUARTER RESULTS
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES PRICING OF EURO-EQUITY FINANCING
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES DOMINION BIOLOGICALS RECEIVES FDA NOTIFICATION OF FINAL SITE INSPECTION FOR NOVACLONE(TM) PRODUCTS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES EXERCISE OF OPTION AND INCLUSION IN TSE 300 COMPOSITE INDEX
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION CLOSES EURO-EQUITY OPTION FOR NEW COMMON SHARES
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES COMPLETION OF THE PURCHASE OF WELLCOME DIAGNOSTICS
INTERNATIONAL MUREX PROMOTES J. DAVID THOLEN TO CHIEF EXECUTIVE OFFICER
INTERNATIONAL MUREX LICENSES TECHNOLOGY TO ABBOTT LABORATORIES
International Murex Reports First Quarter Earnings of $0.10 Per Share

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters